New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis

Abstract

The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University/Hospital for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. We identified 45 patients (38 female, seven male) who received a mean of 9 ± 1 (range 2-23) pulses of intravenous cyclophosphamide for diffuse proliferative glomerulone phritis (n = 28), focal proliferative glomerulonephritis (n = 7), membranous nephropathy (n = 5), mesangial nephropathy with sclerosis (n = 1) or nephritis without biopsy (n = 4). Forty-two of the 45 patients received cyclophosphamide after failing steroid therapy. During a follow-up period of 52 ± 3 months, nine patients progressed to end-stage renal disease (ESRD) with three additional patients experiencing a doubling of the creatinine and two patients persistent nephrotic range proteinuria. There were no deaths directly attributable to cyclophosphamide and no patients developed hemorrhagic cystitis or malignancy. Ten of 37 women had ceased menstruating prior to cyclophosphamide therapy. Treatment-associated amenorrhea occurred in only three patients all over 27 years of age. Intermittent intravenous cyclophosphamide therapy of lupus nephritis is well tolerated and usually effective in maintaining renal function in patients unresponsive to steroids although, in our experience, 20% of patients developed ESRD and a total of 14 of 45 (30%) patients had unsatisfactory outcomes.

Keywords

systemic lupus erythematosus cyclophosphamide nephritis

Get full access to this article

View all access options for this article.

References

Sztejnbok M. , Stewart A. , Diamond H. , Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 1971; 14: 639-45.

Hahn BH , Kantor OS , Osterland CK Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83: 597-605.

Strober S. , Farinas MC , Field EH , Solovera JJ , Kiberd BA , Myers BD , Hoppe RT Treatment of lupus nephritis with total lymphoid irradiation: observations during 12-79 month follow-up. Arthritis Rheum 1989; 84: 922-30.

Kimberly RP , Lockshin MD , Sherman RL et al. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am. J Med 1981; 70: 817-25.

Liebling MR , McLaughlin K. , Boonsue S. , Kasdin J. , Barner EV Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 1982; 9: 543-8.

Lewis EJ , Hunsicker LG , Lan S-P. , Rohde RD , Lachin JM A controlled trial of plasmapheresis therapy in severe lupus nephritis. New Engl J Med 1992; 326: 1373-9.

Steinberg AD , Kaltreider HB , Staples PJ , Goetzl EJ , Talal N. , Decker JL Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971; 75: 165-71.

Donadio J. Jr , Holley KE , Ferguson RH , Ilstrup DM Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. New Engl J Med 1978; 299: 1151-5.

Steinberg AD , Decker JL A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis . Arthritis Rheum 1974; 17: 923-37.

10.

Austin III HA , Klippel JH , Balow JE , LeRiche NG , Steinberg AD , Plotz PH , Decker JL Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986; 314: 614-19.

11.

Balow JE , Austin III HA, Muenz LR. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. New Engl J Med 1984; 311: 491-5.

12.

Steinberg AD , Steinberg SC Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 1991; 34: 945-50.

13.

Boumpas DT , Austin III HA , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5.

14.

Boumpas DT , Austin III HA, Vaughan EMN, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9.

15.

Baldwin DS , Gluck MC , Lowenstein J. , Gallo GR Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 1977; 62: 12-32.

16.

Schieppati A. , Mosconi L. , Perna A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. New Engl J Med 1993; 329: 85-9.

17.

Genuth SM Endocrine Function, Physiology. Berne R , Kelly M (eds). St. Louis, MO: Mosby Books, 1006-12.

18.

McCune WJ , Golbus J. , Zeldes W. , Bohlke P. , Dunne R. , Fox DA Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. New Engl J Med 1988; 318: 1423-51.

19.

Du Lth , Piette J-C. , Faucher C. et al. Efficacy and limits of intravenous cyclophosphamide (IVCP) in systemic lupus erythematosus (SLE). An open study in 45 cases. Arthritis Rheum 1991; 34: S58 (abstract).

20.

Lehman Tja , Sherry DD , Wagner-Weiner L. et al. Intermittent intravenous cyclophosphamide for lupus nephritis . J Pediatr 1989; 114: 1055-60.

21.

Wagner-Weiner L. , Emery H. , Spencer C. , Sisung C. , Magilavy D. Intravenous pulse cyclophosphamide therapy (IVCY) for childhood lupus nephritis: variable renal outcomes at 3 to 7 year follow-up. Arthritis Rheum 1991; 34: S58 (abstract).

22.

Felson DT , Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. New Engl J Med 1984; 311: 1528-33.

23.

Pestiner M. , Wallace DJ , Nessim S. , Metzger AL , Klinenberg JR Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991 ; 21: 55-64.